Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound binds), MC4R (a melanocortin receptor central to satiety), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the metabolic terrain a clinician prescribes into
Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: a nationwide study
They improve blood sugar control and help with weight loss
Joo E, Harada N, Yamane S et al (2017) Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat dietfed mice
While all GLP-1 medications work similarly, individual responses vary
Hormonal changes in perimenopause and menopause Perimenopause (typically 40-50): Estrogen fluctuations (up and down unpredictably) Progesterone decline begins Growth hormone (GH) production dropping Testosterone declining (yes, women need it too) Irregular periods and cycles Menopause (average age 51): Estrogen drops dramatically Progesterone nearly absent GH continues declining Metabolic rate slows 20-30% End of menstrual cycles Post-menopause (50+): Low estrogen becomes new baseline Further GH decline Muscle loss accelerates (sarcopenia) Bone density concerns Continued metabolic challenges Learn about peptides in our what are peptides guide , how peptides work , and what are peptides used for
